|Articles|October 1, 2003

Raptiva rounds hot corner, heads for hotter market

Austin, Texas - Genentech's Raptiva took a significant step toward approval by the U.S. Food and Drug Administration. The psoriasis treatment received a unanimous recommendation from an FDA advisory panel.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME